Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

1724studies indexed776with human data107registered trials1479carry a numeric findingLibrarian added 0 studies today
Showing 26 studiesSortNewest indexed
B
grade
Plasma proteome screen of individuals with elevated blood counts to identify diagnostic signatures and biomarkers inherent to patients with myeloproliferative neoplasms
Erythropoietin (EPO) · biorxiv-preprint · 2026 · Observational
The study identifies TFRC as a promising biomarker for diagnosing polycythemia vera, especially when combined with serum erythropoietin.
Diagnostic accuracy for identifying PV increased to 99.3% when combined with serum erythropoietin.
A
grade
Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.
Erythropoietin (EPO) · Nephrology (Carlton, Vic.) · 2025 · RCT
Efepoetin alfa showed a 6.3% higher response rate compared to methoxy polyethylene glycol-epoetin beta in correcting anemia in CKD patients, but the clinical significance of this difference is uncertain.
Difference in response rates was 6.3% with 95% CI -3.1% to 15.5%.
A
grade
Impact of intravenous iron or exogenous erythropoietin on hemoglobin mass, exercise performance, and acute mountain sickness during altitude acclimatization.
Erythropoietin (EPO) · Journal of applied physiology (Bethesda, Md. : 1985) · 2025 · RCT
Neither intravenous iron nor EPO treatment improved hemoglobin mass, exercise performance, or symptoms of acute mountain sickness during high-altitude exposure.
Absolute Hbmass (g) increased from SL and day 1 to day 13 (P < 0.0001).
B
grade
The impact of multiple long-term conditions on mortality, progression to kidney failure and health-related quality of life among people with chronic kidney disease: a multicentre cohort study (NURTuRE-CKD).
Erythropoietin (EPO) · Annals of medicine · 2026 · Observational · n=2996
Higher numbers of comorbidities in chronic kidney disease patients are linked to increased mortality and worse quality of life, but not to CKD progression.
Adjusted hazard ratios for mortality increased with comorbidity count: 1.37 (2), 1.45 (3), 1.54 (4), and 1.80 (≥5), with significance at ≥4 comorbidities.
D
grade
Casemix-based budget impact analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in the Netherlands.
Erythropoietin (EPO) · Journal of medical economics · 2026 · Observational
Ferric derisomaltose could lead to substantial cost savings compared to ferric carboxymaltose in treating iron deficiency anemia in patients with inflammatory bowel disease.
Potential annual savings are €28.2 million.
B
grade
Continuous calcimimetic use with erythropoiesis-stimulating agent co-administration within a target hemoglobin range is associated with lower mortality in dialysis patients
Erythropoietin (EPO) · biorxiv-preprint · 2026 · Observational
Continuous use of calcimimetics may be associated with lower mortality in dialysis patients receiving ESAs, especially in those with higher EPO doses and certain risk factors.
Adjusted hazard ratio for mortality in calcimimetic users was 0.226, 95% CI 0.058–0.889, P=0.033.
D
grade
Association of pruritus with comorbidities and survival in chronic kidney disease: a narrative review of the pre-difelikefalin era literature.
Erythropoietin (EPO) · europepmc · 2026 · Review
Pruritus in chronic kidney disease is associated with increased mortality, cardiovascular events, and mental health issues, but the significance of these associations can vary based on confounding factors.
18 out of 37 studies found a statistically significant association between CKD-aP and mortality.
B
grade
The association between low hemoglobin-to-red blood cell distribution width ratio and macroalbuminuria in diabetic kidney disease: evidence from NHANES and an external validation cohort.
Erythropoietin (EPO) · europepmc · 2026 · Observational
The study found that lower hemoglobin-to-red blood cell distribution width ratio is associated with macroalbuminuria in diabetic kidney disease, suggesting HRR may serve as a potential marker for this condition.
HRR in macroalbuminuria group: 0.96 ± 0.19 vs microalbuminuria group: 1.01 ± 0.18, p < 0.001.
B
grade
Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
Erythropoietin (EPO) · europepmc · 2026 · Observational
Linezolid may show some efficacy in treating nontuberculous mycobacterial diseases, but the high rate of adverse events and treatment discontinuation warrants caution.
Cumulative incidence rates of relapse and treatment failure were 22.5% and 15.0% at month nine, respectively.
Showing 25 of 26